{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:00:54Z","timestamp":1771920054404,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and different targets. The disruption of O-glycosylation pathway in ovarian and endometrial cancer is associated with cancer growth, metastasis, and poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study we treated\n                      <jats:italic>in vitro<\/jats:italic>\n                      endometrial and ovarian human cancer cell lines with the combination of the monoclonal antibody (mAb) NEO-201 and IL-15 to overcome the resistance of gynecological cancers to immunotherapy. The combination was also used\n                      <jats:italic>in vivo<\/jats:italic>\n                      to treat mice bearing human ovarian cancer. NEO-201 is a humanized IgG1 mAb that binds to core 1 and\/or extended core 1 O-glycans expressed by human cancer cells (including different ovarian cancer subtypes), as well as non-cancerous CD15\n                      <jats:sup>+<\/jats:sup>\n                      granulocytes and immunosuppressive cells. NEO-201 can mediate the killing of its target cells through different mechanisms of action, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). One strategy to enhance ADCC mediated by mAbs is to boost natural killer (NK) cells with IL-15. A previous study showed that IL-15 superagonist complex (N-803) enhanced ADCC activity mediated by NEO-201\n                      <jats:italic>in vitro<\/jats:italic>\n                      against several human carcinoma cells, by modulating NK cells activation and cytotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study we demonstrated that IL-15 enhanced ADCC mediated by NEO-201\n                      <jats:italic>in vitro<\/jats:italic>\n                      against human endometrial and ovarian cancer cell lines expressing NEO-201 target antigen, and that the combination of IL-15 and NEO-201, using purified human NK cells as effectors, had a modest effect in prolonging the survival of mice bearing human ovarian cancer, compared to IL-15 or NEO-201 alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The ability of IL-15 to enhance NEO-201 efficacy, with NK cells as effectors, supports the hypothesis of combining NEO-201 and IL-15 with NK cell therapy (i.e. IL-15-secreting CAR-NK cells with a longer IL-15\n                      <jats:italic>in vivo<\/jats:italic>\n                      half-life and stronger NK activity) for the treatment of gynecological cancers expressing O-glycans recognized by NEO-201.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1652596","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:10Z","timestamp":1771910350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Jamie","family":"Hur","sequence":"first","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Fantini","sequence":"additional","affiliation":[{"name":"Precision Biologics, Inc.","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Korrapati","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah F.","family":"Edmondson","sequence":"additional","affiliation":[{"name":"Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research","place":["Frederick, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Cam","sequence":"additional","affiliation":[{"name":"Center for Cancer Research Collaborative Bioinformatics Resource (CCBR), National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Tandon","sequence":"additional","affiliation":[{"name":"Center for Cancer Research Collaborative Bioinformatics Resource (CCBR), National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]},{"name":"Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research","place":["Frederick, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Cole","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwong Y.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Precision Biologics, Inc.","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Arlen","sequence":"additional","affiliation":[{"name":"Precision Biologics, Inc.","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[{"name":"Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e65638","DOI":"10.7759\/cureus.65638","article-title":"The role of immunotherapy in the treatment of gynecologic cancers: A systematic review","volume":"16","author":"Farajimakin","year":"2024","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122104","article-title":"Drug resistance and immunotherapy in gynecologic cancers","volume":"332","author":"Vemula","year":"2023","journal-title":"Life Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/life14030344","article-title":"Immunotherapy in cervical and endometrial cancer: current landscape and future directions","volume":"14","author":"Stefanoudakis","year":"2024","journal-title":"Life (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00682-w","article-title":"MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition","volume":"34","author":"Friedman","year":"2021","journal-title":"Mod Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102220","article-title":"O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications","volume":"51","author":"Xia","year":"2025","journal-title":"Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030275","article-title":"The role of sialyl-tn in cancer","volume":"17","author":"Munkley","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2016.03.008","article-title":"Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives","volume":"1860","author":"Chia","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.acr.2014.11.002","article-title":"Simple sugars to complex disease--mucin-type O-glycans in cancer","volume":"126","author":"Kudelka","year":"2015","journal-title":"Adv Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14572","article-title":"Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells","volume":"23","author":"Thomas","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133266","article-title":"Role of truncated O-galNAc glycans in cancer progression and metastasis in endocrine cancers","volume":"15","author":"Pinto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-018-1667-8","article-title":"Reduced \u03b1GlcNAc glycosylation on gastric gland mucin is a biomarker of Malignant potential for gastric cancer, Barrett\u2019s adenocarcinoma, and pancreatic cancer","volume":"149","author":"Yamanoi","year":"2018","journal-title":"Histochem Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2000.9776","article-title":"Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions","volume":"31","author":"Davidson","year":"2000","journal-title":"Hum Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02858-z","article-title":"Glycosylation and its research progress in endometrial cancer","volume":"24","author":"Pu","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10020-022-00544-y","article-title":"O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy","volume":"28","author":"Lu","year":"2022","journal-title":"Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107709","article-title":"O-GlcNAcylation in tumorigenesis and its implications for cancer therapy","volume":"300","author":"Zhang","year":"2024","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2397011","article-title":"Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human Malignancies and immune suppressor cells","volume":"23","author":"Fantini","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01899","article-title":"Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas","volume":"8","author":"Fantini","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133037","article-title":"Development and characterization of an anti-cancer monoclonal antibody for treatment of human carcinomas","volume":"14","author":"Tsang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00805","article-title":"Evaluation of the anti-tumor activity of the humanized monoclonal antibody NEO-201 in preclinical models of ovarian cancer","volume":"10","author":"Zeligs","year":"2020","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14204999","article-title":"Identification of the O-glycan epitope targeted by the anti-human carcinoma monoclonal antibody (mAb) NEO-201","volume":"14","author":"Tsang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.v97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2018.2628","article-title":"An IL-15 superagonist, ALT-803, enhances antibody-dependent cell-mediated cytotoxicity elicited by the monoclonal antibody NEO-201 against human carcinoma cells","volume":"34","author":"Fantini","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"B28","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e202451318","DOI":"10.1002\/eji.202451318","article-title":"Tumor glycosylation: A main player in the modulation of immune responses","volume":"55","author":"Rodriguez","year":"2025","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12038","article-title":"HMMC-1, a human monoclonal antibody to fucosylated core 1 O-glycan, suppresses growth of uterine endometrial cancer cells","volume":"104","author":"Oikawa","year":"2013","journal-title":"Cancer Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105753","article-title":"ALCAM\/CD166 is involved in the binding and uptake of cancer-derived extracellular vesicles","volume":"23","author":"Carde\u00f1es","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275904","article-title":"Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy","volume":"14","author":"Fantini","year":"2023","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2099","article-title":"Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action","volume":"180","author":"Dubois","year":"2008","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 trans-signaling with the superagonist RLI promotes effector\/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13046-023-02649-6","article-title":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","volume":"42","author":"Cole","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2530","article-title":"Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab","volume":"42","author":"Hur","year":"2024","journal-title":"JCO"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1652596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:12Z","timestamp":1771910352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1652596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1652596"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1652596","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1652596"}}